Market Overview

Benchmark Initiates Coverage on Exactech with Buy Rating, $21 PT

Share:
Related EXAC
Exactech Receives FDA 510k Clearance for Its Optetrak Logic Constrained Condylar Prosthesis
Whitney Tilson Comments On Personal Holdings At Robin Hood Conference

In a report published earlier today, the Benchmark Company, LLC initiated coverage on Exactech, Inc. (NASDAQ: EXAC) with a Buy rating and a price target of $21.00.

Benchmark went on to say “We believe that the total worldwide market for orthopedic products is in excess of $30 billion. We estimate that the worldwide market for hips, knees and spine products are in excess of $5.0 billion each. While the orthopedic market is a large multi-billion market, we believe that this market is positioned for long-term growth driven by the aging of the population. We believe that the aging of the population will drive an increase in the volume of orthopedic related surgical procedures and therefore an increase in the demand for EXAC's medical devices.”

Exactech, Inc. closed yesterday at $16.50.

Latest Ratings for EXAC

DateFirmActionFromTo
May 2015Northland SecuritiesInitiates Coverage onMarket Perform
Apr 2015Canaccord GenuityDowngradesBuyHold
Mar 2015GabelliInitiates Coverage onBuy

View More Analyst Ratings for EXAC
View the Latest Analyst Ratings

Posted-In: The Benchmark CompanyAnalyst Color Initiation Analyst Ratings

 

Related Articles (EXAC)

View Comments and Join the Discussion!

Get Benzinga's Newsletters